Use Of Consultants For CDMO Selection
Source: ISR Reports
In Q22022, ISR asked 99 outsourcers whether the company they work for uses consultants to help guide their CDMO selection process. Two-fifths (42%) of respondents confirmed the practice. The use of consultants during CDMO selection is popular at both large biopharma companies with an annual R&D of $1B+ and non-large companies with an annual R&D <$1B, (38% and 46%, respectively). Be on the lookout for ISR’s CDMO Outsourcing Models (3rd Edition) for more insights.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more